Clinical trial

Topical Rapamycin to Erase Angiofibromas in TSC

NCT01526356

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-05-01

PhasePHASE2

Study timeline

Study start (unknown)2012-05-01Date precision: month

Registry last updated2020-10-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Angiofibromasunresolved

Tuberous Sclerosisunresolved

Interventions

PlaceboDRUG

RapamycinDRUG

Sponsors & collaborators

The University of Texas Health Science Center, Houstonlead sponsor

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 BirminghamAlabama, United States1 CincinnatiOhio, United States1 OaklandCalifornia, United States1 Saint PaulMinnesota, United States1 SydneyNew South Wales, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01526356 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.